Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome
- 12 June 2026
- journal article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 41 (12) , 4423-4432
Abstract
Mycophenolate mofetil (MMF) as maintenance therapy after rituximab treatment is effective in preventing relapses in children with complicated frequently relapsing or steroid-dependent nephrotic syndrome. However, once sustained remission has been achieved by MMF, the outcomes and risk of relapse after discontinuing MMF remain unclear. We conducted a two-center, retrospective study of patients with childhood-onset frequently relapsing or steroid-dependent nephrotic syndrome who discontinued MMF because of sustained remission for ≥ 2 years on maintenance MMF after rituximab treatment. Relapse, additional treatment, and risk factors for relapses after MMF discontinuation were analyzed. Sixty patients were enrolled. After tapering or discontinuation of MMF, 35 (58%) patients relapsed, and the median time from tapering to relapse was 276 days. The 50% relapse-free survival was 1.5 years using the Kaplan-Meier method. After relapses, 30 (86%) patients required reinitiation of immunosuppressants or additional rituximab treatment. The history of initial steroid-resistant nephrotic syndrome, relapses < 10 times before the first rituximab treatment with immunosuppressants, and a longer period between the last B-cell recovery and tapering MMF were significantly associated with a lower risk of relapse in a multivariate analysis using the Cox proportional hazards model (all p < 0.05). Discontinuation of MMF may be considered in selected patients with sustained remission after rituximab treatment, particularly those with identified low-risk factors for relapse. The timing of discontinuation should be individualized according to these factors and patient-specific considerations because resumption of immunosuppressants or additional rituximab treatment is frequently required after relapse following MMF discontinuation.Keywords
This publication has 23 references indexed in Scilit:
- Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndromeClinical and Experimental Nephrology, 2025
- Feasibility of discontinuing immunosuppression in children with idiopathic nephrotic syndromePediatric Nephrology, 2024
- IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndromePediatric Nephrology, 2022
- Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in childrenCochrane Database of Systematic Reviews, 2020
- Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled studyPediatric Nephrology, 2020
- Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic SyndromeJAMA Pediatrics, 2018
- Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximabPediatric Nephrology, 2017
- Rituximab for nephrotic syndrome in childrenClinical and Experimental Nephrology, 2016
- Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndromePediatric Nephrology, 2011
- Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndromePediatric Nephrology, 2008